ClinicalTrials.gg
CompletedNCT07006792ADsolveUpdated Oct 15, 2026

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

A Phase 4 interventional study of Lebrikizumab in Atopic Dermatitis, sponsored by Eli Lilly and Company. Completed at 66 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Updated Oct 15, 2026Now CompletedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
233
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.

Enrollment
14th of 24
233 · median 252
Started
2025
with 1 other
Phase 4
4 of 24
2 open now
Registered
21st of 24
by date
Lead sponsor
14 of 24
Eli Lilly and Company

Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one is the 14th largest by enrollment, is one of 2 that started in 2025, is one of 4 in phase 4, and was the 21st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing lebrikizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy.

Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have chronic atopic dermatitis (AD) (according to American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year before screening visit.
  • Have 10% to 25% body surface area (BSA) of AD involvement at screening and baseline.
  • Have pruritus numeric rating scale (NRS) ≥6 at baseline.
  • Have an Eczema Area and Severity Index (EASI) score ≥16 at screening and baseline.
  • Have an Investigator's Global Assessment (IGA) score ≥3 (on a scale of 0 to 4) at screening and baseline.
  • Based on investigator judgement, have a history of inadequate response to treatment with topical medications, or determination that topical treatments are otherwise medically inadvisable.
  • For participants aged 12 to less than 18, have a body weight ≥40 kilograms (kg) at baseline.

Exclusion criteria

Exclusion Criteria:

  • Have an uncontrolled chronic disease that might require multiple intermittent uses of oral at screening (as defined by the investigator).
  • Have known liver cirrhosis and/or chronic hepatitis of any etiology.
  • History of , including mycosis fungoides or cutaneous T-cell lymphoma, within 5 years before the screening, except completely treated in situ carcinoma of the cervix of completely treated and resolved nonmetastatic squamous or basal cell carcinoma of the skin with no evidence of recurrence in the past 12 weeks.
  • Are diagnosed with active endoparasitic infections or at high risk of these infections.
  • Have a known or suspected history of , including history of invasive opportunistic infections despite infection resolution; or unusually frequent, recurrent, or prolonged infections, per the investigator's judgment.
  • Have presence of skin comorbidities that may interfere with study assessments.
  • Have a severe concomitant illness(es) that in the investigator's judgment would adversely affect the participant's participation in the study.
  • Have had any of the following types of infection within 3 months of screening or develop any of these infections during screening:

    • Serious (requiring hospitalization, and/or intravenous or equivalent oral antibiotic treatment).
    • Opportunistic - Note: Herpes zoster is considered active and ongoing until all vesicles are dry and crusted over.
    • Chronic (duration of symptoms, signs, and/or treatment of 6 weeks or longer).
    • Recurring (including, but not limited to, recurring cellulitis and chronic osteomyelitis).
  • Have an active or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit or superficial skin infections within 1 week before the baseline visit.
  • Have had any prior treatment with a biologic therapy for AD.
  • Have had treatment with any of the following agents within 4 weeks prior to the baseline visit:

    • systemic immunosuppressive or immunomodulating drugs (for example, systemic corticosteroids, cyclosporine, mycophenolate mofetil, interferon-gamma,
    • azathioprine, methotrexate, and other immunosuppressants)
    • small molecules (for example, Janus kinase inhibitors [topical or systemic]), or
    • phototherapy and photochemotherapy for AD.
  • Treatment with B-cell-depleting biologics, including rituximab, within 6 months prior to baseline.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
233 participants (actual)

Study arms

  • Experimental
    Lebrikizumab

    Lebrikizumab administered subcutaneously (SC).

    Drug: Lebrikizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) (≥75% Reduction from Baseline in EASI), or a ≥4-point Reduction in Pruritus Numerical Rating Scale (NRS) from Baseline

    The primary endpoint will be a composite endpoint as defined by achieving either EASI-75 or Pruritus NRS≥4-point Reduction from Baseline.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving EASI-75

    Time frame: Baseline to Week 24

  2. Percentage of Participants Achieving a ≥4-point Reduction from Baseline in Pruritus NRS

    Time frame: Baseline to Week 24

  3. Percentage of Participants with an Investigator's Global Assessment (IGA) of 0 or 1 and a Reduction ≥2 points from Baseline

    Time frame: Baseline to Week 24

  4. Percentage of Participants Achieving EASI-90

    Time frame: Baseline to Week 24

  5. Change from Baseline in Body Surface Area (BSA) Involvement

    Time frame: Baseline, Week 24

  6. Percentage of Change from Baseline in Pruritus NRS Score

    Time frame: Baseline, Week 24

  7. Percentage of Participants with a Sleep-loss Scale Score of ≥2 points at Baseline Who Achieve a ≥ 2-point Reduction

    Time frame: Baseline to Week 24

  8. Percentage Change from Baseline in Sleep-loss Scale

    Time frame: Baseline, Week 24

  9. Percentage of Participants with a Skin Pain NRS of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction

    Time frame: Baseline to Week 24

  10. Change from Baseline in Dermatology Quality of Life (DLQI)

    Time frame: Baseline, Week 24

  11. Change from Baseline in Children's Dermatology Quality of Life (CDLQI)

    Time frame: Baseline, Week 24

07

Study locations

66 sites
  • Total Skin & Beauty Dermatology Center, PC DBA Total Dermatology
    Birmingham, Alabama 35203, United States
  • Research Solutions of Arizona
    Litchfield Park, Arizona 85340, United States
  • Alliance Dermatology and Mohs Center
    Phoenix, Arizona 85032, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • NorCal Clinical Research
    Rocklin, California 95765, United States
  • Suncoast Research Associates
    Doral, Florida 33172, United States
  • Encore Medical Research
    Hollywood, Florida 33024, United States
  • Solutions Through Advanced Research
    Jacksonville, Florida 32256, United States
  • Life Arc Research Centers - Miami
    Miami, Florida 33126, United States
  • MCR Research
    Miami, Florida 33126, United States
  • Health Clinical Research
    Miami, Florida 33176, United States
  • Deluxe Health Center
    Miami Lakes, Florida 33014, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Leading Edge Dermatology
    Plantation, Florida 33317, United States
  • Dermatology Affiliates Research Institute
    Atlanta, Georgia 30305, United States
  • DeNova Research
    Chicago, Illinois 60602, United States
  • Southern Indiana Clinical Research Center
    Columbus, Indiana 47201, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • Southern Indiana Clinical Trials
    New Albany, Indiana 47150, United States
  • Equity Medical - Bowling Green
    Bowling Green, Kentucky 42104, United States
  • Allergy & Asthma Specialists, P.S.C.
    Owensboro, Kentucky 42301, United States
  • Foxhall Research Center
    Chevy Chase, Maryland 20815, United States
  • Great Lakes Research Group, Inc.
    Bay City, Michigan 48706, United States
  • Revival Research Institute, LLC
    Troy, Michigan 48084, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • Equity Medical
    New York, New York 10023, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Hickory Dermatology Research Center
    Hickory, North Carolina 28602, United States
  • ObjectiveHealth - Goodlettsville Dermatology Research
    Goodlettsville, Tennessee 37072, United States
  • Reveal Research Institute - Frisco
    Frisco, Texas 75033, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77084, United States
  • Prime Clinical Research - Mansfield
    Mansfield, Texas 76063, United States
  • Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue
    San Antonio, Texas 78235, United States
  • Jordan Valley Dermatology & Research Center
    South Jordan, Utah 84095, United States
  • CONEXA Investigacion Clinica S.A.
    Buenos Aires, 1012, Argentina
  • CIPREC
    Buenos Aires, 1061, Argentina
  • Centro de Investigaciones Metabólicas (CINME)
    Buenos Aires, C1056ABI, Argentina
  • DOM Centro de Reumatología
    Buenos Aires, C1111, Argentina
  • Instituto de Neumonologia Y Dermatologia
    Buenos Aires, C1425BEA, Argentina
  • Psoriahue
    Buenos Aires, C1425DKG, Argentina
  • Fundación Respirar
    Buenos Aires, C1426ABP, Argentina
  • Parra Dermatología
    Mendoza, 5500, Argentina
  • INECO Neurociencias Oroño
    Rosario, 2000, Argentina
  • Instituto de Investigaciones Clinicas Rosario
    Rosario, S2000CVD, Argentina
  • Centro de Investigaciones San Miguel
    San Miguel, 1663, Argentina
  • AlergoAlpha - Barueri
    Barueri, 06454-010, Brazil
  • PUC Trials- Nucleo de Pesquisa clinica da Escola de Medicina da PUCPR
    Curitiba, 80230-130, Brazil
  • Irmandade da Santa Casa de Misericórdia de Porto Alegre
    Porto Alegre, 90050-170, Brazil
  • Hospital São Lucas da PUCRS
    Porto Alegre, 90610-000, Brazil
  • IBPClin - Instituto Brasil de Pesquisa Clínica
    Rio de Janeiro, 20241-180, Brazil
  • Centro de Pesquisas da Clínica IBIS
    Salvador, 41820-020, Brazil
  • Faculdade de Medicina do ABC
    Santo André, 09060-870, Brazil
  • ISPEM - Instituto São José dos Campos em Pesquisas Médicas
    São José dos Campos, 12243-280, Brazil
  • CEPIC - Centro Paulista de Investigação Clínica
    São Paulo, 04266-010, Brazil
  • Brunswick Dermatology Center
    Fredericton, E3B 1G9, Canada
  • Maritime Dermatology
    Halifax, B3K 5R3, Canada
  • Lovegrove Dermatology
    London, N6A 5R9, Canada
  • Skin Care West
    Nanaimo, V9V 1A3, Canada
  • Kanata Allergy Clinic
    Ottawa, K2T 0N7, Canada
  • SKiN Centre for Dermatology
    Peterborough, K9J 5K2, Canada
  • Centre de Recherche Saint-Louis
    Sherbrooke, J1G 1X9, Canada
  • Eternal Springtime Dermatology
    Thunder Bay, P7C 4Y7, Canada
  • North York Research Inc
    Toronto, M2N 3A6, Canada
  • Dr. Samuel Sanchez PSC
    Caguas, 00725, Puerto Rico
  • CMRC Headlands, LLC
    San Juan, 00918, Puerto Rico
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in May 2026, 10 months.

Of 45 phase 4 interventional studies under Dermatitis, Atopic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2025
First posted
Jun 5, 2025
StartActual
Jun 16, 2025
Primary completionActual
May 14, 2026
CompletionActual
Sep 21, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07006792
Responsible party
Sponsor
First posted
Jun 5, 2025
Start date
Jun 16, 2025
Primary completion
May 14, 2026
Completion
Sep 21, 2026
Last update
Oct 15, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion